
    
      The proposed clinical trial is the first-in-human, single-center, open-label, systemic gene
      delivery study of SRP-9003 LGMD2E patients. Up to six patients will be enrolled in 2 cohorts.
      Based on data from Cohort 1, there is a potential to escalate dose for Cohort 2. LGMD2E is
      also referred to as LGMDR4.
    
  